Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors
To evaluate the plasma level of 8-isoprostanes in women with polycystic ovary syndrome. To also investigate whether there is a relationship between 8-isoprostanes and several cardiovascular risk factors.
A total of 125 women with polycystic ovary syndrome and 169 healthy women were enrolled in this case–control study. 8-Isoprostanes and different parameters were measured in all subjects. Patients were evaluated for the presence of polycystic ovary syndrome according to the Rotterdam Consensus Conference criteria.
8-Isoprostanes levels were significantly higher in patients with polycystic ovary syndrome (138.4 ± 104.1 pg/mL) compared with control group (68.6 ± 34.3 pg/mL) (p < 0.001). The mean of triglycerides, lipid accumulation product, C-reactive protein, homocysteine, insulin, and homeostatic model assessment for insulin resistance were significantly higher in polycystic ovary syndrome patients with high 8-isoprostanes than those with normal 8-isoprostanes (p < 0.05). The Pearson correlation analyses showed that 8-isoprostanes levels in polycystic ovary syndrome group had a positive correlation with waist circumference, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, homocysteine, insulin, homeostatic model assessment for insulin resistance.
Patients with polycystic ovary syndrome have higher 8-isoprostanes levels and it is associated with several cardiovascular risk factors.
KeywordsPolycystic ovary syndrome Insulin resistance Oxidative stress 8-Isoprostanes Infertility
The authors thank all the women for participating in this study. We also thank the nursing staff for their help.
This work was supported by a grant from the Institute of Health Carlos III (ISCIII) (no PI13/01237).
Compliance with ethical standards
Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
The authors declared that the manuscript has not been submitted to more than one journal for simultaneous consideration and it has not been published previously. No data have been fabricated or manipulated to support your conclusions. No data, text, or theories by others are presented as if they were the author’s own. This study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time. Consent to submit has been received explicitly from all co-authors, as well as from the hospital where the work has been carried out. All authors have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.
In this controlled study participants were voluntarily recruited and they all signed an informed consent.
- 17.Kaya C, Erkan AF, Cengiz SD, Dunder I, Demirel OE, Bilgihan A (2009) Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril 92(4):1372–1377CrossRefGoogle Scholar
- 27.Caballero Balanza S, Martorell Aragones A, Cerda Mir JC, Belda Ramirez J, Navarro Ivanez R, Navarro Soriano A et al (2010) Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J Investig Allergol Clin Immunol 20(3):237–243PubMedGoogle Scholar
- 34.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefGoogle Scholar